CorMedix Q3 prelim rev >$100M, raises FY25 pro forma guidance to at least $375M

CorMedix Inc.

2025-Q3 EPS reported $1.97 vs consensus $0.66 ▲ beat (+199.3%)

Q3 2025 preliminary net revenue >$100M; DefenCath revenue >$85M; pro forma net revenue >$125M.
FY25 pro forma net revenue guidance raised from $325-350M to at least $375M.
Q3 adjusted EBITDA expected at least $70M; ~$30M cost synergies on run-rate basis by year-end.
Phase III ReSPECT study of Rezzayo fully enrolled; data expected 2Q 2026.
Cash and equivalents ~$56M at Sep 30; projected year-end cash ~$100M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.